In People magazine: From his hospital bed, Robbie Fox and Kelli Peters, both 27, said “I do” just 10 days before he succumbed to Ewing sarcoma. The couple got engaged in March 2025, after Fox went into remission following treatment at @danafarber.bsky.social. ➡️bit.ly/4uUTwoz

ICYMI: Featured on @wbztv.bsky.social: @danafarber.bsky.social and @boston.gov announce funding to help preserve access to comprehensive early cancer screenings for Boston firefighters who are often exposed to carcinogens and toxic smoke in the line of duty. ➡️ bit.ly/4tTFCBL

ICYMI: “I could not be more appreciative and more grateful to the incredible team at Dana-Farber,” Boston Firefighters IAFF Local 718 President Sam Dillon told @bostonglobe.com regarding @danafarber.bsky.social’s pledge to help fund @boston.gov’s firefighter cancer screening program. bit.ly/3Rv7DSI

Dr. Paul Richardson of @danafarber.bsky.social presents results from SUCCESSOR-2 study showing the oral drug mezigdomide markedly improved PFS in patients w/relapsed or refractory multiple myeloma. Results support this novel therapy as a possible new standard of care for RRMM. #ASCO26 bit.ly/4wUzw6z

Featured on @boston25news.com: Work has begun on @danafarber.bsky.social new 300-bed inpatient facility expected to open in 2031. It will be the region’s only hospital dedicated exclusively to adult cancer care. ▶️bit.ly/42X2QMf

Two plenary studies and additional late-breaking research to be presented by @danafarber.bsky.social at #ASCO26. Be sure to check out these impactful oral presentations in Chicago. ▶️bit.ly/3RwURmD

The @americancancersoc.bsky.social updated guidelines, adding a blood test option, to increase #ColorectalCancer screenings. @danafarber.bsky.social’s Dr. Kimmie Ng told @nbcnews.com this highlights the significance of catching as many people as possible at risk for colorectal cancer. bit.ly/4tUSYNX

Vitamin D analog shuts down pancreatic cancer’s shield in clinical trial - new research from @danafarber.bsky.social’s and @salkinstitute.bsky.social published in @natcancer.nature.com. Read more: bit.ly/4fbfHlc

New research in @natmed.nature.com by @danafarber.bsky.social’s Dr. Suzanne George and Dr. Bradley Bernstein reveals the clinical activity of FGFR inhibition in SDH-deficient GIST. ➡️bit.ly/497QeW8 @broadinstitute.org

FDA approval of adjuvant atezolizumab for ctDNA-positive muscle-invasive bladder cancer marks a major advance in precision oncology, helping personalize treatment after cystectomy. @danafarber.bsky.social’s Dr. Joaquim Bellmunt helped lead the IMvigor011 study supporting approval. bit.ly/3PZdIpQ

More than 75 @danafarber.bsky.social studies will be presented at #ASCO26, including studies in pancreatic and prostate cancer selected for the plenary program and additional late-breaking research in breast cancer and multiple myeloma. Read more here: bit.ly/4ui1kAe

Research in @natcomms.nature.com by @danafarber.bsky.social’s David Barbie, MD, demonstrates protein tyrosine phosphatase non-receptor type 2 inhibition can unleash STING agonist response, providing a rationale for the evaluation of this therapeutic combination in head & neck cancer. bit.ly/49PPWmP

ICYMI: At ONS Congress, @danafarber.bsky.social’s Elianna Tobin, BSN, RN, OCN, shared findings with @curetoday.bsky.social on how nurse navigator outreach helped patients feel more prepared before cancer appointments. ➡️bit.ly/49ffUjv #ONS26

New research in @natchembio.nature.com co-authored by Itay Algov, Phd, in @danafarber.bsky.social’s Xin Zhou Lab and Audrey Van Heest in Boston University’s Hao Lab introduces PSurf, a yeast peptide display platform that identifies protease substrates in tissue-derived samples. bit.ly/4wrXE0c

Watch ABC News Live report on a pill showing promise in treating metastatic pancreatic cancer. @danafarber.bsky.social is leading research in this area, and Dr. Brandon Huffman details his experience enrolling patients in these clinical trials. ➡️bit.ly/3RaHSqE

Congratulations to the 10 @danafarber.bsky.social nurses whose patients nominated them for the @bostonglobe.com’s Salute to Nurses for moments of connection that shaped their experiences and outcomes in ways that transcend clinical care. ➡️bit.ly/4dkprac

Today, the Massachusetts Public Health Council unanimously approved our Determination of Need to build a proton therapy center at our Longwood Campus. This new center will expand access to lifesaving proton therapy for more pediatric and adult patients across the region.

"New treatments offer hope for deadly pancreatic cancer" - @danafarber.bsky.social’s Dr. Brian Wolpin featured on @npr.org’s 'All Things Considered' ➡️bit.ly/3R7QU7F

A new study from @danafarber.bsky.social’s Dr. Jose Pablo Leone in @jamanetworkopen.com shows incidence and proportion of stage 4 breast cancer increasing over the past decade. ➡️bit.ly/4nkKmhS

FDA approval in cholangiocarcinoma: The FDA has approved zenocutuzumab for NRG1+ Cholangiocarcinoma. @danafarber.bsky.social’s Dr. James Cleary helped lead research of the drug in this rare cancer type which has had limited treatment options. ➡️bit.ly/4dlQ8vg

We’re on our way to #ONS26, which takes place from May 13-17 in San Antonio. Read more about notable presentations by @danafarber.bsky.social nurses and researchers showcasing oncology nursing science, evidence-based practice, education and leadership initiatives at bit.ly/4njTuU0#ONS26

Congratulations to @danafarber.bsky.social’s @ireneghobrial.bsky.social and Robert Haddad, MD, who are among the 2026 Giants of Cancer Care inductees announced by @onclive.bsky.social. Read more here: bit.ly/4fdvX51

In the @bostonglobe.com's Salute to Nurses, @danafarber.bsky.social nurse Brianna O’Brien notes how AI cannot replace human connection. “When patients trust their nurses, they might reveal a new symptom or ask hard questions. And that honesty can drive better outcomes,” O’Brien said. bit.ly/3PayMJO

Just published in @nejm.org: RAS(ON) Inhibitor daraxonrasib shows promising results in advanced pancreatic cancer phase 1/2 study. @danafarber.bsky.social's Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research, is a lead investigator on the trial. bit.ly/4uvpS8w

As #NursesWeek gets underway, @danafarber.bsky.social patient Sister Nancy Sheridan pays tribute to Sandy Cohen, RN, and Cheri Manzi, RN, and their warm friendship which extends beyond the clinic where Nancy has been treated for stage 4 ovarian cancer for 8 years. bit.ly/4d7oxOf#NursesWeek#NationalNursesDay

“There is something in our environment that is likely contributing to early-onset colorectal cancer.” A Perspective in @natmed.nature.com from Dr. Kimmie Ng and @danafarber.bsky.social researchers highlights the promise and the caution around emerging epigenetic research. ➡️bit.ly/4tNG6Kr

Closing out #headandneckcancer Awareness Month with a powerful message in @curetoday.bsky.social from @danafarber.bsky.social’s Dr. Robert Haddad describing how immunotherapy before and after surgery is reshaping treatment and the overall importance of early evaluation. ➡️bit.ly/4w05JJf

We’re proud to share that we’ve been ranked #5 among 60 institutes and centers in the 2026 Cure Innovation Index Ranking—a national benchmark measuring how effectively U.S. biomedical research institutions turn discovery into real-world health impact.

Benjamin L. Ebert, MD, PhD, president and CEO, has been elected to the National Academy of Sciences (@nasonline.org) in recognition of his distinguished and continuing achievements in cancer research. Please join us in congratulating him on this honor.

New research in @natmicrobiol.nature.com by @aragucci.bsky.social of @danafarber.bsky.social’s @kranzuschlab.bsky.social highlights the mechanistic diversity of nuclease-NTPase systems in bacterial immunity and provides a resource for others studying these systems. ➡️ bit.ly/4sVD0CH

In this interview with @onclive.bsky.social, @danafarber.bsky.social’s Dr. Vinayak Venkataraman spotlights a focus-group study identifying mobility, autonomy, and supportive care gaps in adolescent and young adults with sarcoma. ➡️ bit.ly/4cETCbS

Congratulations to @danafarber.bsky.social’s Alan D’Andrea, MD, and Judy Garber, MD, on their election to the American Academy of Arts and Sciences. ➡️bit.ly/4tvhFBb

Featured on Healthcare Brew: @danafarber.bsky.social’s food pantry recently launched with support from Stop & Shop to help combat #foodinsecurity and advance health equity during cancer treatment. Read more: bit.ly/4sMhTCP#foodinsecurity

April is #HeadAndNeckCancer Awareness Month, a time to raise awareness about cancers affecting the mouth, throat, larynx, sinuses and salivary glands and the importance of early detection. Learn about symptoms, risk factors, prevention and treatment options: bit.ly/4lrJlDg#HeadAndNeckCancer @danafarber.bsky.social

We’re getting ready to wrap up #AACR26 today, but not before once again congratulating @danafarber.bsky.social’s Eliezer Van Allen, MD, and Kimberly Stegmaier, MD, recipients of @theaacr.bsky.social 2026 Scientific Achievement Awards. ➡️bit.ly/4mpIN1Q

Today at #AACR26: Noah Fields, MS, in the lab of @danafarber.bsky.social’s Dr. Eliezer Van Allen, presents findings from a familial cancer study suggesting that high-resolution germline genetic testing could benefit patients with familial cancer. ➡️ bit.ly/4crIeQl#AACR26

In a Phase II Clinical Trials poster session, @danafarber.bsky.social’s Dr. Catherine Marinac shares results from a clinical trial in MGUS and smoldering myeloma suggesting short-term metformin may lead to modest improvements in M-protein levels. More research is needed. #AACR26 ➡️ bit.ly/48088JN#AACR26

Today at #AACR26: @danafarber.bsky.social’s Kristen Brantley, PhD, presents study findings highlighting the importance of recommending endocrine therapy for patients facing hormone-receptor positive breast cancer, and of improving treatment adherence by increasing tolerability. ➡️ bit.ly/3OIEe6j#AACR26

New research at #AACR26: @danafarber.bsky.social’s @abdohlman.bsky.social shares results from the largest pan-cancer microbiome analysis to date using metagenomic sequencing. This work unlocks a map of the tumor-associated microbial environment that can help future studies. ➡️ bit.ly/3Q7TytH

Today at #AACR26 @zeyunlu.bsky.social, a research fellow in @sashagusevposts.bsky.social’s lab at @danafarber.bsky.social, presents findings that LLM-based extraction of unstructured clinical notes can provide scalable and accurate characterization of immune-related side effects. ➡️ bit.ly/4mxMtyF

At the #AACR26 press conference, Dr. Omar Nadeem of @danafarber.bsky.social presents results of the phase 2 CAR-PRISM clinical trial, the first to investigate CAR T-cell therapy in pts with high-risk smoldering multiple myeloma. The study also published today at @natmed.nature.com: bit.ly/3Qpatba

Congratulations to @danafarber.bsky.social's Dr. Toni Choueiri who was elected to the Association of American Physicians in recognition of his contributions in basic or translational biomedical research. Read more: bit.ly/4cQw9pn

At #AACR26: Results from CAR-PRISM Trial. Dr. Omar Nadeem says in a small trial for pts with high-risk smoldering myeloma, "This is the 1st time we've seen universal minimal residual disease negativity with a one-time treatment administration." @danafarber.bsky.social ➡️ bit.ly/4tmxcmW

In today’s Clinical Trials Plenary at #AACR26: @danafarber.bsky.social’s Dr. Elizabeth Lee reports promising results from a phase 1 study exploring toxicity reduction in combination therapy with trastuzumab deruxtecan and olaparib in advanced HER2-expressing malignancies. ➡️ bit.ly/3OvT1B5#AACR26

Dr. Alice Shaw @danafarber.bsky.social will highlight emerging science shaping the future of global cancer research and clinical care in today’s #AACR26 Opening Plenary. Learn more: brnw.ch/21wRXs0

Congratulations to @danafarber.bsky.social’s Dr. Alice Shaw, Dr. Kimberly Stegmaier and Dr. Matthew Vander Heiden who were elected as Fellows of the @theaacr.bsky.social Academy Class of 2026. Read more: bit.ly/4suWu0L

#AACR26 kicks off today and we’re proud to highlight over 50 studies including #myeloma, #pancreaticcancer, #breastcancer, #AI and genetic risk factors presented by @danafarber.bsky.social researchers. bit.ly/4cAoXMU#AACR26

New research from @danafarber.bsky.social Kornelia Polyak, MD, PhD, published in @cp-cancercell.bsky.social reveals key mechanisms by which precancerous ductal carcinoma in situ (DCIS) turns into invasive breast cancer. ➡️ bit.ly/4dNXcmf

We’re on our way to #AACR26! Whether you’ll be in San Diego from April 17-22 or attending virtually, follow @danafarbernews.bsky.social for important research findings by @danafarber.bsky.social faculty across a spectrum of cancers. Complete list of DFCI oral abstracts: bit.ly/4sDdXEu#AACR26

“It's a reason for optimism.” @danafarbernews.bsky.social's Andrew Aguirre, MD, PhD, discusses data released this week on the pancreatic cancer drug daraxonrasib, an oral pill that is a multi-selective RAS inhibitor. Read more here: bit.ly/4tg1l7t